【Invitation】CPHI Chin☆¶a 2024 | Haibu Pharma★≠ceutical invites you to meet in Shanα∞δghai - June 19-21

Classification:

Recent Events

Release time:

2024-06-12

The 22nd World Pharmaceut§←ical Raw Materials China Exhibition
 
Date: June 19-21, 2024→€γ
Location: Shanghai New In≈©₽ternational Expo Center (Pudong)
The 22nd World Pharmac☆<≈eutical Raw Materials C↑¥↑hina Exhibition (CPhI China 2÷σ←'024) will continue t ∏←o partner with the 17th World λ→÷Pharmaceutical Machinery, Packagi ÷ng Equipment and Materials China Exhi§<☆bition (PMEC China 2024), showcasing∞φ over 3,500 domestic ≤  and international exhibitors and ¶≈™ an exhibition area of overΩσ§↓ 210,000 square meters at the Shanghai ₩>New International Expo Center×✔.
CPhI & PMEC global series exhibit×★δδions are leading brand exhibi¶♠' tions in the pharmaceu☆$tical industry, with fo♥§otprints across China, Europe, North Am€✔‍Ωerica, Southeast Asia, tπ∑he Middle East, Japan, Sou₹≈th Korea, and India. They have receiα←ved widespread recognition Ω¶↕and active participation from global ₩Ωpharmaceutical profeγ€‍ssionals. Leveraging high-qua宥∑lity overseas audience resources∞$♠∏ from the series of exhibitions ✔↑and over twenty years of a←∑↓≈ccumulation in China, CPh"×π✘I & PMEC China E↕"xhibition has grown into ←↓an important window for Chinese enα™♦≠terprises to enter the global stage an ®​d for overseas exhibi ↕←tors to enter the Chin→♣₽♥ese market.
1. Haibu Exhibition Hall and Booth Guγ✘¥→idance

Chemical Drug CRO Services₩ ★

Registration and Commercial Supp÷∏ly Related to APIs

Customs and Commercial Supply o∏♣ δf Advanced Pharmaceutical I≤'☆≈ntermediates

Research and Cooperation on New δ↑Coupling Drug Technologies

MAH Formulation R&D and∏∑ Licensing

Import and Export of Drugsβ↓‌$/Technologies

Beijing Haibu Pharmaceutical•×£↔ Technology Co., Ltd. (refe↕&rred to as 'Haibu Pharmaceuφ∞tical') was established in 2005 as a hi®ε♦§gh-tech enterprise with 'chemical drug ©€∏R&D' as its core​ ÷® capability. It has a÷↓  Beijing R&D center, a‍∑₹≥n API and formulation ✘≠βpilot verification center, ☆→✘a GMP industrial productio""n base, mainly engaged in CRO s✔€φ™ervices for APIs and formulations, MAH★‍ joint licensing, API-related de★α≤clarations, as well as±ε÷ commercial supply of ph±©$÷armaceutical intermediates.It has rich experience in ε‌₩ R&D transfer production, r≠®♠egistration declaration of various→✘ dosage forms such as chemicaΩ¥÷l APIs, oral solids, liquid formu≈₩✔lations, sterile injectionsπΩ₽, external preparations etc. The R&£ amp;D products cover multiple th↕≈€erapeutic areas including anti-tumor, a>>nti-depression, anti↕≤φ-epilepsy, anti-anxiety, caσ rdiovascular diseases, digestive system Ω diseases, respiratory sys★★λλtem diseases etc.

Haibu Pharmaceutical ★£has been awarded the≤δ®≤ title of 'Top 20 Chinese P→£harmaceutical R&D Compani•✔δ×es' for several consecutive yea≥"£rs and recognized as<✔←₽ a 'Specialized & In ♥↕novative Enterprise' by Beijing M≈✔unicipality; a 'National High-tech Eββ→nterprise'; a 'Beijing Science &≈✔♦ Technology Research Development I<¥nstitution'; a 'Beijing λφ&Yizhuang Enterprise Innovation Center',≠✘ among others.